Imlygic (talimogene laherparepvec, T-VEC) medical necessity
Customize your policy alerts
Sign up for Mass General Brigham Health Plan Policy 115 alerts
Get alerted when Policy 115 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing, exclusions, and coding guidance for Imlygic (T-VEC) for treatment of unresectable melanoma lesions for Mass General Brigham Health Plan members across lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Imlygic (T-VEC)
Initial Approval
Covered when ALL of the following are met
Authorization may be granted if all conditions are satisfied.
Dosing and Administration
Dosing guidance relevant to administration
Used to inform administration and billing.
The policy includes explicit exclusions. Members who are immunocompromised and members who are pregnant are listed as excluded from coverage for Imlygic in the provided policy excerpts.
Reference materials cited in this policy that address locoregional management (including in-transit disease and local recurrence) include UpToDate and the Ontario Health (Cancer Care Ontario) guideline; these sources are listed for clinical context and do not themselves introduce additional explicit exclusions in the supplied excerpts.
Within the provided document excerpts there are no statements declaring Imlygic "not medically necessary"; the references section and cited guidelines are bibliographic and do not contain any 'not medically necessary' language in the supplied text.
Coding and Dosing Details
| J9325 | Injection, talimogene laherparepvec, per 1 million plaque forming units |
Prior Authorization, Documentation, and Denials
Obtain prior authorization per payer rules (J9325)
Prior authorization is required for Commercial, Mass General Brigham ACO, One Care/SCO, and Commercial/Qualified Health Plan members; Medicare Advantage follows CMS guidance and may not require a separate plan-level PA when CMS guidance applies. Follow the payer-specific routing noted below when submitting requests for J9325 (Injection, talimogene laherparepvec, per 1 million PFU).
- Commercial and Qualified Health Plans: Prior authorization managed by Prime Therapeutics; see Prime Therapeutics policy for submission details.
- Mass General Brigham ACO: Prior authorization required; MassHealth Drug List criteria (Table 57: Oncology Agents) are used for determinations.
- One Care and SCO: Prior authorization required; follows CMS guidance and if Medicare criteria are not met, MassHealth criteria apply.
- Medicare Advantage: Mass General Brigham Health Plan uses CMS (NCD/LCD/LCA and Medicare manuals) guidance for determinations; when CMS documentation references FDA labeling, plan applies additional coverage criteria.
No additional PA conditions listed in references
The policy excerpts provide bibliographic references and guideline citations but do not list additional or alternative prior authorization conditions beyond the payer routing and CMS/MassHealth references; use the plan- or Prime Therapeutics–specified PA criteria when available.
- References and guidelines are cited (ESMO, NCCN, ASCO, pivotal trials, package insert) but do not replace payer-specific PA submission requirements.
Route Commercial prior authorization to Prime Therapeutics
For Commercial and Qualified Health Plan members, prior authorization processing and any related step therapy checks are handled by Prime Therapeutics; providers must submit PA requests via Prime Therapeutics and follow their policy requirements.
- Check the Prime Therapeutics Imlygic policy for any programmatic step therapy or PA prerequisites before submission.
No step therapy requirements specified
No step therapy rules for Imlygic are present in the supplied policy content; providers should confirm with Prime Therapeutics or the applicable payer if step edits apply prior to authorization or claim submission.
- If Prime Therapeutics policy or the payer imposes step therapy, follow those external requirements; none are specified in the Mass General Brigham policy text.
Use CMS or MassHealth documentation standards for payer-specific submissions
Follow CMS guidance or the MassHealth Drug List criteria for required documentation for Medicare Advantage, One Care/SCO, and Mass General Brigham ACO members as applicable; commercial PA documentation requirements are defined by Prime Therapeutics.
- Medicare Advantage & One Care/SCO: Use NCDs, LCDs, LCAs, and Medicare manuals as the basis for medical necessity and documentation.
- Mass General Brigham ACO: Use MassHealth Drug List criteria (Table 57) for documentation when applicable.
- Commercial: Submit documentation required by Prime Therapeutics for PA review.
No detailed documentation checklist provided — submit clinical evidence supporting criteria
The policy excerpts and reference pages do not specify granular documentation elements (e.g., exact forms, imaging, or pathology reports) required for PA; providers must supply the clinical information requested by the payer or Prime Therapeutics to demonstrate the member meets initial approval criteria.
- Provide documentation that supports all Initial Approval criteria (diagnosis of unresectable melanoma, recurrence after initial surgery, and lesions that are cutaneous/subcutaneous/nodal and unresectable).
- If the payer requests additional clinical details, submit operative reports, pathology, and prior treatment history as directed.
Denial risk if Initial Approval criteria or exclusions are not documented
Requests that do not meet ALL Initial Approval criteria or that involve excluded populations may be denied; specifically, lack of documented unresectable melanoma diagnosis, absence of recurrence after surgery, lesions not meeting the specified sites, immunocompromised status, or pregnancy are denial risks.
- Denial triggers include failure to document: (a) diagnosis of unresectable melanoma; (b) recurrence after initial surgery; (c) lesions that are unresectable and cutaneous, subcutaneous, and/or nodal.
- Requests for members who are immunocompromised or pregnant may be denied per exclusions.
References only — no separate denial rules listed
The provided reference pages list only bibliographic sources and guideline citations and do not contain standalone denial rules; rely on the policy's stated criteria and exclusions when assessing risk of denial.
- References (ESMO, NCCN, ASCO, trials, package insert) inform clinical context but do not substitute for documentation of the policy's approval criteria.
Background and Indication
Imlygic (talimogene laherparepvec, T-VEC) is an oncolytic herpesvirus indicated for local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions recurrent after surgery. The policy notes that Imlygic has not been shown to improve overall survival or to treat visceral metastases, and that clinical evidence supports activity particularly in earlier-stage injectable disease and as an option within guideline-recommended locoregional management strategies.
Definitions
Line of Therapy Guidance
salvage
Line (first/second) not explicitly specified in the source; used as salvage/local therapy option.
first-line
Document discusses first-line contexts in cited evidence and guideline references; policy does not explicitly mandate a single-line placement.
Regimens and Combinations
| Regimen | Evidence summary / setting | Coverage label |
|---|---|---|
| T-VEC + ipilimumab | Phase II randomized trial (5-year final analysis) showed objective response rate 39% for combination vs 18% for ipilimumab alone; median OS 24.0 vs 18.9 months (Chesney et al., 2023). | Informational |
| T-VEC + pembrolizumab | MASTERKEY-115 (phase II) in patients progressed on prior anti-PD-1 therapy showed modest activity with ~11% objective response rate, indicating limited benefit in PD-1–refractory settings (Robert et al., 2024). | Informational |
| T-VEC combined with checkpoint inhibitors (general) | Combination strategies have been a major focus of development; efficacy varies by clinical setting (neoadjuvant, advanced injectable disease) and by prior anti–PD-1 exposure. Neoadjuvant data suggest event-free survival benefit in select trials. | Informational |
| Regimen | Trial / source | Coverage label |
|---|---|---|
| Imlygic (T-VEC) monotherapy | Systematic reviews and meta-analyses and single-agent studies summarize activity in stage IIIB–IVM1c and earlier injectable disease; package insert and evidence syntheses cited. | Informational |
| Imlygic + ipilimumab | Phase II randomized trial (Chesney et al., 2023) demonstrated higher response rates and improved median OS versus ipilimumab alone in advanced melanoma (5-year final analysis). | Informational |
| Imlygic + pembrolizumab | MASTERKEY-115 (Robert et al., 2024) evaluated T-VEC + pembrolizumab in patients who progressed on prior anti–PD-1 therapy and reported modest response (~11%), indicating limited benefit in the anti–PD-1–refractory population. Neoadjuvant randomized trial follow-up also supports exploration of T-VEC before surgery. | Informational |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.